Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecast to 2027
The global minimal residual disease testing market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0% during the forecast period. Market growth is driven by rise in the number of patients with cancer and hematological malignancies, growing awareness drives regarding cancer by government, and increasing collaborations and partnerships between companies.
“The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period”
The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market. Device being easy to use, easy accessibility of assay kits, and a good sensitivity are the major factors contributing the large share of this segment.
“Hematological Malignancies applications segment accounted for the highest CAGR”
Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.
“Asia Pacific: The fastest-growing region minimal residual disease testing market”
The global minimal residual disease testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.
The Asia Pacific minimal residual disease testing market is estimated to grow at the highest CAGR during the forecast period, primarily due to improving healthcare infrastructure, the presence of a large pool of patient population, the rising focus of key players in the region, government efforts to increase awareness about the detection of diseases, continuously rising healthcare expenditures, an increasing number of hospitals & clinical diagnostic laboratories in India and China, and the strengthening research base for diagnostic procedures across India, China, and Japan.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the global minimal residual disease testing market. It aims at estimating the size and future growth potential of the market across different segments, such as technology, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall minimal residual disease testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
“The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period”
The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market. Device being easy to use, easy accessibility of assay kits, and a good sensitivity are the major factors contributing the large share of this segment.
“Hematological Malignancies applications segment accounted for the highest CAGR”
Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.
“Asia Pacific: The fastest-growing region minimal residual disease testing market”
The global minimal residual disease testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.
The Asia Pacific minimal residual disease testing market is estimated to grow at the highest CAGR during the forecast period, primarily due to improving healthcare infrastructure, the presence of a large pool of patient population, the rising focus of key players in the region, government efforts to increase awareness about the detection of diseases, continuously rising healthcare expenditures, an increasing number of hospitals & clinical diagnostic laboratories in India and China, and the strengthening research base for diagnostic procedures across India, China, and Japan.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%
- By Designation: C-level - 30%, D-level - 20%, and Others - 50%
- By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, Latin America –9%, and the Middle East & Africa – 3%
- Labcorp Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Guardant Health (US)
- Sysmex Corporation (Japan)
- NeoGenomics Laboratories, Inc. (US)
- Adaptive Biotechnologies Corporation (US)
- ArcherDX, Inc. (US)
- Asuragen Inc. (US)
- Arup Laboratories Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Cergentis B.V. (Netherlands)
- Molecular MD (ICON plc) (Ireland)
- Invivoscribe, Inc. (US)
- Mission Bio, Inc. (US)
- Natera, Inc. (US)
- Opko Health, Inc. (US)
- Quest Diagnostics (US)
- Genetron Health (China)
This report provides a detailed picture of the global minimal residual disease testing market. It aims at estimating the size and future growth potential of the market across different segments, such as technology, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall minimal residual disease testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS COVERED
1.3.1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
FIGURE 12 RISING INCIDENCE OF CANCER TO DRIVE MARKET
4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET IN 2027
4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 14 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2027
4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 15 HOSPITALS & SPECIALTY CLINICS LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING
4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of hematological malignancies
TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
5.2.1.3 Increasing cancer awareness initiatives by global health organizations
5.2.2 RESTRAINTS
5.2.2.1 Complex regulatory frameworks delaying approval of new molecular diagnostics tests
5.2.2.2 High cost of minimal residual disease testing kits
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in minimal residual disease testing in emerging countries
TABLE 3 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030
5.2.4 CHALLENGES
5.2.4.1 Unclear reimbursement scenario and policies for patients
5.3 PRICING ANALYSIS
TABLE 4 AVERAGE SELLING PRICE OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS (2022)
5.4 PATENT ANALYSIS
FIGURE 18 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET
5.4.1 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET ANALYSIS
FIGURE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM/MARKET ANALYSIS
TABLE 5 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY ANALYSIS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.9.3.2 Japan
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS
TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017–2021 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 16 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCT MANUFACTURERS
FIGURE 22 REVENUE SHIFT IN MINIMAL RESIDUAL DISEASE TESTING MARKET
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP THREE APPLICATIONS
TABLE 17 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
5.14.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
TABLE 18 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
5.15 CASE STUDY ANALYSIS
6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
6.2 POLYMERASE CHAIN REACTION
6.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
TABLE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION)
6.3 NEXT-GENERATION SEQUENCING
6.3.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO BOOST MARKET
TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)
6.4 FLOW CYTOMETRY
6.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO SUPPORT GROWTH
TABLE 22 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)
6.5 OTHER TECHNOLOGIES
TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2 HEMATOLOGICAL MALIGNANCIES
TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2020–2027 (USD MILLION)
7.2.1 LEUKEMIA
TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
7.2.1.1 Myeloid leukemia
7.2.1.1.1 High prevalence of AML in adults to support growth
TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.1.2 Lymphocytic leukemia
7.2.1.2.1 High incidence of ALL in children to drive market
TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.1.3 Other leukemias
TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)
7.2.2 LYMPHOMA
TABLE 32 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
TABLE 33 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
7.2.2.1 Non-Hodgkin lymphoma
7.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
TABLE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.2.2.2 Hodgkin lymphoma
7.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel MRD testing
TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.3 SOLID TUMORS
7.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2020–2027 (USD MILLION)
7.4 OTHER APPLICATIONS
TABLE 37 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER
8.1 INTRODUCTION
TABLE 38 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2 HOSPITALS & SPECIALTY CLINICS
8.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
TABLE 39 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2020–2027 (USD MILLION)
8.3 DIAGNOSTIC LABORATORIES
8.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
8.4 ACADEMIC & RESEARCH INSTITUTES
8.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 41 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
8.5 OTHER END USERS
TABLE 42 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION
9.1 INTRODUCTION
TABLE 43 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
TABLE 44 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 46 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 Increasing prevalence of cancer to drive market
TABLE 48 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 49 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 50 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Availability of various cancer screening programs to support market growth
TABLE 51 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 52 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 53 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3 EUROPE
TABLE 54 EUROPE: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2020–2035
TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 57 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Government support for research funding to support MRD testing market
TABLE 59 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
TABLE 60 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 61 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 62 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Increasing number of diagnostic laboratories to propel market growth
TABLE 63 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 64 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 65 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising R&D expenditure in France to drive market
TABLE 66 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 67 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 68 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Favorable funding scenario to drive market
TABLE 69 ITALY: CANCER INCIDENCE, BY TYPE, 2020
TABLE 70 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 71 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 72 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Consolidation of laboratories in Spain to support market growth
TABLE 73 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 74 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 75 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 76 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 77 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 78 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
TABLE 79 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Growing public access to advanced healthcare facilities to drive market
TABLE 83 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 84 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 85 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 86 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Universal healthcare reimbursement policy to support market growth
TABLE 87 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 88 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 89 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 90 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Increasing private and public investments in healthcare system to drive market
TABLE 91 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 92 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 93 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 94 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2019
TABLE 95 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 96 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 97 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
TABLE 98 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 99 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 100 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
TABLE 101 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER (2021)
TABLE 105 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT
10.5.1 LIST OF EVALUATED VENDORS
10.5.2 STARS
10.5.3 EMERGING LEADERS
10.5.4 PERVASIVE PLAYERS
10.5.5 PARTICIPANTS
FIGURE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS, 2021
10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
10.7 COMPETITIVE BENCHMARKING
10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS
TABLE 106 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGIONAL FOOTPRINT OF COMPANIES
TABLE 107 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT OF COMPANIES
TABLE 108 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
TABLE 109 KEY PRODUCT LAUNCHES
10.8.2 DEALS
TABLE 110 KEY DEALS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats)*
11.1.1 ADAPTIVE BIOTECHNOLOGIES
TABLE 111 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
11.1.2 ARCHERDX (INVITAE CORPORATION)
TABLE 112 ARCHERDX (INVITAE CORPORATION): BUSINESS OVERVIEW
FIGURE 33 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2021)
11.1.3 ASURAGEN, INC.
TABLE 113 ASURAGEN, INC.: BUSINESS OVERVIEW
11.1.4 BIO-RAD LABORATORIES, INC.
TABLE 114 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
11.1.5 F. HOFFMANN-LA ROCHE AG
TABLE 115 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
11.1.6 GUARDANT HEALTH, INC.
TABLE 116 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 36 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
11.1.7 MOLECULARMD (SUBSIDIARY OF ICON PLC)
TABLE 117 MOLECULAR MD (SUBSIDIARY OF ICON PLC): BUSINESS OVERVIEW
FIGURE 37 MOLECULAR MD (ICON PLC): COMPANY SNAPSHOT (2021)
11.1.8 INVIVOSCRIBE, INC.
TABLE 118 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
11.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 119 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
11.1.10 NATERA, INC.
TABLE 120 NATERA, INC.: BUSINESS OVERVIEW
FIGURE 39 NATERA, INC.: COMPANY SNAPSHOT (2021)
11.1.11 SYSMEX CORPORATION
TABLE 121 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 40 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
11.2 OTHER PLAYERS
11.2.1 NEOGENOMICS LABORATORIES
11.2.2 OPKO HEALTH, INC.
11.2.3 GENETRON HEALTH
11.2.4 QUEST DIAGNOSTICS, INC.
11.2.5 ARUP LABORATORIES INC.
11.2.6 MISSION BIO, INC.
11.2.7 CERGENTIS B.V.
*Details on Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS COVERED
1.3.1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
FIGURE 12 RISING INCIDENCE OF CANCER TO DRIVE MARKET
4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET IN 2027
4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 14 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2027
4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 15 HOSPITALS & SPECIALTY CLINICS LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING
4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of hematological malignancies
TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
5.2.1.3 Increasing cancer awareness initiatives by global health organizations
5.2.2 RESTRAINTS
5.2.2.1 Complex regulatory frameworks delaying approval of new molecular diagnostics tests
5.2.2.2 High cost of minimal residual disease testing kits
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in minimal residual disease testing in emerging countries
TABLE 3 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030
5.2.4 CHALLENGES
5.2.4.1 Unclear reimbursement scenario and policies for patients
5.3 PRICING ANALYSIS
TABLE 4 AVERAGE SELLING PRICE OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS (2022)
5.4 PATENT ANALYSIS
FIGURE 18 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET
5.4.1 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM/MARKET ANALYSIS
FIGURE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM/MARKET ANALYSIS
TABLE 5 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REGULATORY ANALYSIS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.9.3.2 Japan
TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS
TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017–2021 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 16 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCT MANUFACTURERS
FIGURE 22 REVENUE SHIFT IN MINIMAL RESIDUAL DISEASE TESTING MARKET
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP THREE APPLICATIONS
TABLE 17 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
5.14.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
TABLE 18 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
5.15 CASE STUDY ANALYSIS
6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
6.2 POLYMERASE CHAIN REACTION
6.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
TABLE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION)
6.3 NEXT-GENERATION SEQUENCING
6.3.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO BOOST MARKET
TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)
6.4 FLOW CYTOMETRY
6.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO SUPPORT GROWTH
TABLE 22 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)
6.5 OTHER TECHNOLOGIES
TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2 HEMATOLOGICAL MALIGNANCIES
TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2020–2027 (USD MILLION)
7.2.1 LEUKEMIA
TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
7.2.1.1 Myeloid leukemia
7.2.1.1.1 High prevalence of AML in adults to support growth
TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.1.2 Lymphocytic leukemia
7.2.1.2.1 High incidence of ALL in children to drive market
TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.1.3 Other leukemias
TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)
7.2.2 LYMPHOMA
TABLE 32 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
TABLE 33 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
7.2.2.1 Non-Hodgkin lymphoma
7.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
TABLE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.2.2.2 Hodgkin lymphoma
7.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel MRD testing
TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.3 SOLID TUMORS
7.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2020–2027 (USD MILLION)
7.4 OTHER APPLICATIONS
TABLE 37 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER
8.1 INTRODUCTION
TABLE 38 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2 HOSPITALS & SPECIALTY CLINICS
8.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
TABLE 39 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2020–2027 (USD MILLION)
8.3 DIAGNOSTIC LABORATORIES
8.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
8.4 ACADEMIC & RESEARCH INSTITUTES
8.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 41 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
8.5 OTHER END USERS
TABLE 42 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION
9.1 INTRODUCTION
TABLE 43 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
TABLE 44 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 46 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 Increasing prevalence of cancer to drive market
TABLE 48 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 49 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 50 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Availability of various cancer screening programs to support market growth
TABLE 51 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 52 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 53 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3 EUROPE
TABLE 54 EUROPE: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2020–2035
TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 57 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Government support for research funding to support MRD testing market
TABLE 59 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
TABLE 60 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 61 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 62 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Increasing number of diagnostic laboratories to propel market growth
TABLE 63 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 64 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 65 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising R&D expenditure in France to drive market
TABLE 66 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 67 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 68 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Favorable funding scenario to drive market
TABLE 69 ITALY: CANCER INCIDENCE, BY TYPE, 2020
TABLE 70 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 71 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 72 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Consolidation of laboratories in Spain to support market growth
TABLE 73 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 74 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 75 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 76 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 77 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 78 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
TABLE 79 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Growing public access to advanced healthcare facilities to drive market
TABLE 83 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 84 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 85 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 86 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Universal healthcare reimbursement policy to support market growth
TABLE 87 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 88 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 89 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 90 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Increasing private and public investments in healthcare system to drive market
TABLE 91 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 92 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 93 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 94 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2019
TABLE 95 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 96 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 97 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
TABLE 98 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 99 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 100 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
TABLE 101 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER (2021)
TABLE 105 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT
10.5.1 LIST OF EVALUATED VENDORS
10.5.2 STARS
10.5.3 EMERGING LEADERS
10.5.4 PERVASIVE PLAYERS
10.5.5 PARTICIPANTS
FIGURE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS, 2021
10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
10.7 COMPETITIVE BENCHMARKING
10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS
TABLE 106 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGIONAL FOOTPRINT OF COMPANIES
TABLE 107 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT OF COMPANIES
TABLE 108 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
TABLE 109 KEY PRODUCT LAUNCHES
10.8.2 DEALS
TABLE 110 KEY DEALS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats)*
11.1.1 ADAPTIVE BIOTECHNOLOGIES
TABLE 111 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
11.1.2 ARCHERDX (INVITAE CORPORATION)
TABLE 112 ARCHERDX (INVITAE CORPORATION): BUSINESS OVERVIEW
FIGURE 33 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2021)
11.1.3 ASURAGEN, INC.
TABLE 113 ASURAGEN, INC.: BUSINESS OVERVIEW
11.1.4 BIO-RAD LABORATORIES, INC.
TABLE 114 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
11.1.5 F. HOFFMANN-LA ROCHE AG
TABLE 115 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
11.1.6 GUARDANT HEALTH, INC.
TABLE 116 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 36 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
11.1.7 MOLECULARMD (SUBSIDIARY OF ICON PLC)
TABLE 117 MOLECULAR MD (SUBSIDIARY OF ICON PLC): BUSINESS OVERVIEW
FIGURE 37 MOLECULAR MD (ICON PLC): COMPANY SNAPSHOT (2021)
11.1.8 INVIVOSCRIBE, INC.
TABLE 118 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
11.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 119 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
11.1.10 NATERA, INC.
TABLE 120 NATERA, INC.: BUSINESS OVERVIEW
FIGURE 39 NATERA, INC.: COMPANY SNAPSHOT (2021)
11.1.11 SYSMEX CORPORATION
TABLE 121 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 40 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
11.2 OTHER PLAYERS
11.2.1 NEOGENOMICS LABORATORIES
11.2.2 OPKO HEALTH, INC.
11.2.3 GENETRON HEALTH
11.2.4 QUEST DIAGNOSTICS, INC.
11.2.5 ARUP LABORATORIES INC.
11.2.6 MISSION BIO, INC.
11.2.7 CERGENTIS B.V.
*Details on Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
